ArticleWellcome open research2024

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Daniel Silman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.